Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant (KRdvsRd)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04096066
Recruitment Status : Recruiting
First Posted : September 19, 2019
Last Update Posted : September 19, 2019
Sponsor:
Information provided by (Responsible Party):
Fondazione Neoplasie Sangue Onlus

Brief Summary:
The combination of lenalidomide plus low-dose dexamethasone (Rd) is considered the new standard for elderly newly diagnosed multiple myeloma (NDMM) patients. The combination carfilzomib plus lenalidomide-dexamethasone (KRd) in relapsed-refractory MM patients improved the progression-free survival (PFS) of approximately 1 year compared to standard Rd treatment. In a small phase 2 trial (23 pts) the KRd combination in elderly NDMM pts showed a complete response (CR) rate of 79% and a PFS at 3 years of 80%. Cardiovascular adverse events are the most limiting toxicities, especially in elderly patients.

Condition or disease Intervention/treatment Phase
Multiple Myeloma New Diagnosis Tumor Drug: Carfilzomib Drug: Lenalidomide Drug: Dexamethasone Phase 3

Detailed Description:

This protocol is a randomized, multicenter study designed to determine the MRD negativity and the PFS of KRd treatment regimen.

Patients will be randomized in a 1:1 ratio to receive carfilzomib-lenalidomide-dexamethasone (KRd - Arm A) or lenalidomide-dexamethasone (Rd - Arm B).

Patients will be stratified basing on international staging system (ISS) and fitness status using a web-based procedure completely concealed to study participants.

All consecutive patients ≥ 65 years with newly diagnosed MM will be enrolled in a large randomized study during a period of 24 months.

Patients will be treated until disease progression or intolerance to the therapy. The only exception is for patients enrolled in KRd arm who achieve at least a VGPR during the first year of treatment and in sustained MRD negativity (MRD negative at least at 10-5 after one and two years of therapy): these patients will stop carfilzomib administration after 2 years, whereas treatment with lenalidomide and dexamethasone will be continued.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 340 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Carfilzomib - Lenalidmide - Dexamethasone (KRd) Versus Lenalidomi - Dexamethasone (Rd) in Newly Diagnosed Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation: a Randomized Phas III Trial
Actual Study Start Date : July 1, 2019
Estimated Primary Completion Date : July 1, 2024
Estimated Study Completion Date : July 1, 2024


Arm Intervention/treatment
Experimental: KRd

Carfilzomib (K):

  • 20 mg/m2 IV on day 1 of cycle 1;
  • 56 mg/m2 IV on days 8 and 15 in cycle 1;
  • 56 mg/m2 IV on days 1, 8 and 15 in cycles 2-12;
  • 56 mg/m2 on days 1 and 15 from cycle 13 and onwards.

Lenalidomide (R):

- 25 mg orally on days 1-21 of each cycle.

Dexamethasone (d):

- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycle.

Until PD or intolerance. Only patients that achieve at least a VGPR within the first year of treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib after 2 years of treatment, and will continue with lenalidomide and dexamethasone administration.

Drug: Carfilzomib
  • 20 mg/m2 IV on day 1 of cycle 1 enhanced to 56 mg/m2 on days 8, and 15 of cycle 1;
  • 56 mg/m2 IV on days 1, 8 and 15 in cycles 2-12;
  • 56 mg/m2 IV on days 1 and 15 from cycle 13 and onwards.

Drug: Lenalidomide
- 25 mg orally on days 1-21 of each cycle.

Drug: Dexamethasone

- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is to be repeated every 28 days. Patients that achieve at least a VGPR within the first year of study treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib administration after 2 years and will continue with lenalidomide and dexamethasone treatment until disease progression or intolerance to the therapy. Other patients will continue carfilzomib administration until disease progression or intolerance.

For patients >75 years of age, the dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each treatment cycle.


Active Comparator: Rd

Lenalidomide (R):

-25 mg orally on days 1-21 of each cycle.

Dexamethasone (d):

-40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycles.

Until PD or intolerance.

Drug: Lenalidomide
- 25 mg orally on days 1-21 of each cycle.

Drug: Dexamethasone

- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is to be repeated every 28 days. Patients that achieve at least a VGPR within the first year of study treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib administration after 2 years and will continue with lenalidomide and dexamethasone treatment until disease progression or intolerance to the therapy. Other patients will continue carfilzomib administration until disease progression or intolerance.

For patients >75 years of age, the dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each treatment cycle.





Primary Outcome Measures :
  1. Minimal residual disease (MRD) [ Time Frame: 5 years ]
    1. Minimal residual disease (MRD): unit of measure is not applicable, MRD is expressed as a pure number

  2. Progression-free survival (PFS) [ Time Frame: 5 years ]
    2. Progression-free survival (PFS): unit of measure is not applicable, PFS is expressed as a pure number


Secondary Outcome Measures :
  1. Rate of drug reduction or drug discontinuation [ Time Frame: 5 years ]
    Incidence of dose reduction and drug discontinuation in both treatment arms.

  2. Cardiovascular assessment [ Time Frame: 5 years ]
    Benefit of proper cardiovascular baseline assessment and monitoring during treatment in both treatment arms:to mitigate major cardiovascular adverse event incidence, to prolong duration of treatment, to improve efficacy.

  3. Rate of dose reduction, drug discontinuation and toxicities [ Time Frame: 5 years ]
    Safety as rate of dose reduction, drug discontinuation and toxicities

  4. Response rate [ Time Frame: 5 years ]
    Response rate will include complete response (CR), very good partial response (VGPR) and partial response (PR) using the International Response Criteria. Responders are defined as subjects with at least a PR.

  5. Progression-free survival 2 (PFS2) [ Time Frame: 5 years ]
    Time from randomization to objective tumor progression on next-line treatment or death from any cause.

  6. Time to progression (TTP) [ Time Frame: 5 years ]
    Time to progression will be measured from the date of randomization to the date of first observation of PD, or deaths related to PD.

  7. Duration of response (DOR) [ Time Frame: 5 years ]
    Time between first documentation of response and PD. Responders without disease progression will be censored either at the time of lost to FU, at the time of death due to other cause than PD, or at the end of the study.

  8. Overall survival (OS) [ Time Frame: 5 years ]
    Time between randomization and death. Subjects who die will be censored at time of death as an event, regardless cause of death.

  9. Time to next therapy (TNT) [ Time Frame: 5 years ]
    Time to next therapy will be measured from the date of randomization to the date of next anti-myeloma therapy. Death due to any cause before starting therapy will be considered an event.

  10. MRD negativity [ Time Frame: 5 years ]
    Correlation between MRD negativity and PFS, PFS2, TTP, TNT and OS

  11. Prognostic factors [ Time Frame: 5 years ]

    The following outcomes will be analysed in subgroups with different prognostic factors:

    • Progression-free survival (PFS),
    • Time to second disease progression (PFS2),
    • Time to progression (TTP),
    • Time to next therapy (TNT ),
    • Overall survival (OS)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Newly diagnosed symptomatic MM based on either standard CRAB criteria (at least 10% of clonal bone marrow plasma cells plus CRAB defined as the onset of any of the following clinical symptoms: hypercalcemia, renal failure, anemia and bone lesions) or at least 10% of bone marrow plasma cells plus the presence of at least one of the following biomarkers of malignancy:

    • 60% or greater clonal plasma cells on bone marrow examination;
    • Serum involved/uninvolved free light chain (FLC) ratio of 100 or greater;
    • More than one focal lesion on magnetic resonance imaging (MRI) that is at least 5 mm or greater in size.
  • Patient not eligible for ASCT (age ≥ 65 years or abnormal cardiac, pulmonary and liver function).
  • Patient defined as fit or intermediate according to the IMWG (International Myeloma Working Group) frailty score
  • Patient has given voluntary written informed consent.
  • Patient is able to be compliant with hospital visits and procedures required per protocol.
  • Patient agrees to use acceptable methods for contraception.
  • Patient has measurable disease according to IMWG criteria.
  • Patient has ECOG (Eastern Cooperative Oncology Group) performance status < 3.
  • Pre-treatment clinical laboratory values within 30 days before randomization:

    • Platelet count ≥50 x 109/L (≥30 x 109 /L if myeloma involvement in the bone marrow is > 50%)
    • Absolute neutrophil count (ANC) ≥ 1 x 109/L without the use of growth factors
    • Corrected serum calcium ≤14 mg/dL (3.5 mmol/L)
    • Alanine transaminase (ALT): ≤ 3 x the ULN
    • Total bilirubin: ≤ 2 x the ULN
    • Calculated or measured creatinine clearance: ≥ 30 mL/minute.
  • LVEF≥ 40%: 2-D transthoracic echocardiogram (ECHO) is the preferred method of evaluation; multigated Acquisition Scan (MUGA) is acceptable if ECHO is not available
  • Pre-treatment blood pressure value < 140/90 mmHg even with adequate therapy: 24 hours blood pressure monitoring is the preferred method of evaluation; blood pressure diary at home for 2 weeks is acceptable.
  • Females of childbearing potential (FBCP) comply with the conditions of the Pregnancy Prevention Plan, including confirmation that she has an adequate level of understanding.
  • FBCP must follow the Pregnancy Prevention Plan and use a highly effective and an additional barrier contraception method simultaneously for 4 weeks before starting therapy, during treatment and dose interruptions and for at least 30 days after the last dose of study drugs*
  • Males must use an effective barrier method of contraception if sexually active with FCBP during the treatment and for at least 90 days after the last administration of study drug/s. Male subjects must agree to refrain from sperm donation for at least 90 days after the last dose of carfilzomib.

Exclusion Criteria:

  • Serious medical condition, laboratory abnormality or psychiatric illness that prevented the subject from the screening or place the subject at unacceptable risk.
  • Patient defined as frail according to the IMWG frailty score.
  • Previous treatment with anti-myeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of steroid < to the equivalent of dexamethasone 40 mg/day for 4 days).
  • Pregnant or lactating females.
  • Presence of:

    • Clinical active infectious hepatitis type A, B, C or HIV
    • Acute active infection requiring antibiotics or infiltrative pulmonary disease
    • Pulmonary hypertension and interstitial lung disease
    • Uncontrolled arrhythmias or history of QT prolongation
    • Myocardial infarction or unstable angina ≤ 6 months or other clinically significant heart disease
    • Peripheral neuropathy or neuropathic pain grade 2 or higher, as defined by National Cancer Institute Common Toxicity Criteria (NCI CTC) 5.0 (Appendix A)
    • Uncontrolled hypertension defined as persistent hypertension (>140/90 mmHg) regardless treatment with 3 drugs, including a diuretic.
  • Contraindication to any of the required drugs or supportive treatments and hypersensitivity to any excipient of the study drugs.
  • Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib).
  • Invasive malignancy within the past 3 years.
  • Administration of any experimental drug within 4 weeks prior the baseline or within 5 drug half-lives.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04096066


Contacts
Layout table for location contacts
Contact: Mario Boccadoro 0116336107 clinicaltrialoffice@emnitaly.org

Locations
Layout table for location information
Italy
FO.NE.SA.Onlus Recruiting
Torino, Italy, 10126
Contact: Mario Boccadoro, MD    +390116336107    clinicaltrialoffice@emnitaly.org   
Sponsors and Collaborators
Fondazione Neoplasie Sangue Onlus
Layout table for additonal information
Responsible Party: Fondazione Neoplasie Sangue Onlus
ClinicalTrials.gov Identifier: NCT04096066    
Other Study ID Numbers: EMN20
First Posted: September 19, 2019    Key Record Dates
Last Update Posted: September 19, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Fondazione Neoplasie Sangue Onlus:
Multiple Myeloma
AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE
Proteasome inhibitor
Immunomodulating agents
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone
Lenalidomide
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Immunologic Factors
Angiogenesis Inhibitors
Angiogenesis Modulating Agents